Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa.

BACKGROUND Recombinant technology was used to produce a new anticoagulant that is preferentially localized and active at the site of the clot. METHODS AND RESULTS The variable regions of the heavy and light chains of a fibrin-specific antibody were amplified by polymerase chain reaction (PCR) with hybridoma cDNA. To obtain a functional single-chain antibody (scFv), a linker region consisting of (Gly(4)Ser)(3) was introduced by overlap PCR. After the scFv clones were ligated with DNA encoding the pIII protein of the M13 phage, high-affinity clones were selected by 10 rounds of panning on the Bbeta15-22 peptide of fibrin (beta-peptide). Hirudin was genetically fused to the C-terminus of the variable region of the light chain. To release the functionally essential N-terminus of hirudin at the site of a blood clot, a factor Xa recognition site was introduced between scFv(59D8) and hirudin. The fusion protein was characterized by its size on SDS-PAGE (36 kDa), by Western blotting, by its cleavage into a 29-kDa (single chain alone) and 7-kDa (hirudin) fragment, by its binding to beta-peptide, and by thrombin inhibition after Xa cleavage. Finally, the fusion protein inhibited appositional growth of whole blood clots in vitro more efficiently than native hirudin. CONCLUSIONS A fusion protein was constructed that binds to a fibrin-specific epitope and inhibits thrombin after its activation by factor Xa. This recombinant anticoagulant effectively inhibits appositional clot growth in vitro. Its efficient and fast production at low cost should facilitate a large-scale evaluation to determine whether an effective localized antithrombin activity can be achieved without systemic bleeding complications.

[1]  M. Little,et al.  Fibrin Targeting and Thrombin Inhibition After Activation by Factor Xa Construction and Functional Evaluation of a Single-Chain Antibody Fusion Protein With , 2000 .

[2]  V. Fuster,et al.  Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin. , 1998, Circulation.

[3]  J. Weitz,et al.  Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. , 1998, Circulation.

[4]  J. Chesebro.  Direct thrombin inhibition superior to heparin during and after thrombolysis: dose, duration, and drug. , 1997, Circulation.

[5]  M. Little,et al.  Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. , 1997, Protein engineering.

[6]  E. Haber,et al.  Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting. , 1997, Circulation.

[7]  M. Little,et al.  High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. , 1997, Journal of immunological methods.

[8]  D. Abendschein,et al.  Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[9]  J. Loscalzo,et al.  Thrombin inhibitors in fibrinolysis. A Hobson's choice of alternatives. , 1996, Circulation.

[10]  V. Fuster,et al.  Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin. , 1996, Circulation.

[11]  E. Braunwald,et al.  Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty. , 1995, Journal of the American College of Cardiology.

[12]  V. Fuster,et al.  Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. , 1994, Circulation.

[13]  M. Little,et al.  Recombinant single-chain Fv fragments carrying C-terminal cysteine residues: production of bivalent and biotinylated miniantibodies. , 1994, Molecular immunology.

[14]  E. Haber,et al.  Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin. , 1994, Circulation.

[15]  V. Fuster,et al.  Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. , 1994, Circulation.

[16]  D. Rigel,et al.  Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis. , 1993, Circulation research.

[17]  T. W. Love,et al.  A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G. Matthyssens,et al.  Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase. , 1991, The Journal of biological chemistry.

[19]  J. B. Lazar,et al.  Hirudin: amino-terminal residues play a major role in the interaction with thrombin. , 1991, The Journal of biological chemistry.

[20]  J. Hirsh.  Drug therapy : heparin , 1991 .

[21]  D. Massel,et al.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.

[22]  E. Haber,et al.  Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator. , 1990, Circulation.

[23]  E. Haber,et al.  Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. , 1983, Science.